In a retrospective study of 168 patients with AML in CR who underwent allo-SCT, we compare the impact of young unrelated donors (UD) vs older matched related donors (MRD) on 5-year OS (5-yr OS). Median follow-up was 59 months and median donor age was 39 years, which was used as cutoff for young vs older donors. Kaplan-Meier-estimated 5-yr OS was better with UD p39 years vs MRD 439 years (66% vs 34%, P ¼ 0.001). In multivariate analysis, only donor age and cytogenetic risk impacted 5-yr OS. Compared with UD p39 years, both MRD 439 years (relative risk (RR): 4.31, P ¼ 0.001) and UD 439 years (RR: 2.14, P ¼ 0.03) were associated with poorer 5-yr OS. Standard-risk cytogenetics was associated with better 5-yr OS compared with bad-risk cytogenetics, (RR: 0.53, P ¼ 0.02). Subgroup analyses of patients X50 years (n ¼ 76) revealed similar results, with 5-yr OS of 62% for UD p39 yrs and 26% for MRD 439 yrs (P ¼ 0.022). In patients undergoing allo-HSCT for AML, young UD may improve outcome as compared with older MRD.
INTRODUCTION
Allo-SCT has been shown to improve relapse free survival and OS in patients with intermediate and poor-risk AML. 1 AML is today one of the most common indications for allogeneic hematopoietic SCT (allo-HSCT). The incidence of AML in adults is higher in elderly patients and the disease is associated with unfavorable characteristics in this patient group. 2, 3 A matched sibling donor (matched related donor, MRD) is generally considered to be the donor of first choice and is preferable to a matched unrelated donor (MUD). It has been reported before that younger donor age may positively influence the outcome of allo-HSCT. [4] [5] [6] Although such analyses are easily feasible for unrelated donor (UD) transplantation, they are hard to perform for sibling donors because patient age will increase along with donor age.
In this retrospective study we evaluate the influence of donor age on the outcome of MRD and UD allo-HSCT, and compare the impact of young UD vs older related donors on 5-yr OS.
PATIENTS AND METHODS
We performed a retrospective analysis of 168 consecutive patients (12 children , that is, o18 years old and 158 adults, that is, X18 years old) transplanted for AML in CR between January 2000 and December 2009 at our center. Seventy-six (76) patients (45%) were X50 years old. It is well recognized that the biology of AML and transplant outcome may vary between the above mentioned patient groups. All patients were, however, included in the study to enable an analysis of the impact of donor age in the whole patient population. Subgroup analyses were limited by patient number. All patients had given written informed consent, and treatment was performed in studies approved by the local ethics committee.
Bad-risk disease was defined as cytogenetics with monosomy 7, trisomy 8 or complex karyotypes, whereas other karyotypes were considered standard risk. Median follow-up was 59 (29-79) months. The median age of donors was 39 years , and this was used as the cutoff point for young and old donors. Accordingly, four donor groups were assigned: UD p39 years, UD 439 years, MRD p39 years and MRD 439 yrs. Median donor age was 37 years (20-60 years) for UD and 45 years (4-78 years) for sibling donors, Po0.001. Median patient age was 51 years (3.3-69.1 years) for UD and 45 years (2.7-70.8 years) for related donors, P ¼ 0.18. Analyses were performed for the 168 patients in CR at time of transplant and separately for all adult patients (n ¼ 156), and for patients older than 50 years (n ¼ 76). Patient characteristics are summarized in Table 1 .
Donor selection and HLA typing HLA-A, -B and -C were typed to the two-digit or four-digit allelic level, HLA-DRB1 and DQB1 were resolved to the four-digit allelic level. Helmberg-Score software was used for allelic assignment in conjunction with the most recent nomenclature report and library. [7] [8] [9] In all, 50 patients received grafts from 10/10 or 8/8 HLA-MUD, 67 patients from HLA-identical sibling donors, 1 patient from HLAmismatched sibling and 50 patients from HLA-mismatched UD. Because 50% of unrelated donor transplants were HLA-mismatched, we refer to this group as UD rather than MUD. 10 All recipients of grafts from MRD p39 years received SIC, whereas only 65% of recipients of grafts from UD p39 years received SIC. Further, 45% and 61% of recipients of grafts from UD 439 years and MRD 439 years received SIC, respectively.
Conditioning regimens

GvHD prophylaxis
All patients received CYA (3 mg/kg i.v.), starting on day À 1 and either additional short-course MTX (10 mg/m 2 ) on days þ 1, þ 3 and þ 6 or mycophenolate mofetil (4 Â 500 mg) daily (day þ 1 to þ 30) after transplantation. Ninety five percent of recipients of grafts from UD received antithymocyte globulin (ATG; ATG-Fresenius, Fresenius, Graefelfing, Germany or Thymoglobulin, Genzyme, Neu-Isenburg, Germany) within the last 3 days prior to transplantation, at a dose of 60-90 mg/kg (ATGFresenius) or 6-8 mg/kg BW (Thymoglobulin), whereas only 28% of recipients of grafts from MRD received ATG-Fresenius at a total dose of 30 mg/kg.
Grading of GvHD
The grading of acute GvHD was performed according to standard criteria. The grades were assigned on the severity of acute GvHD of skin, liver and gastrointestinal tract. 11 Chronic GvHD was evaluated in patients alive beyond day þ 80 post transplant and characterized as 'limited' or 'extensive'. 12 Supportive care
All patients were nursed in reverse isolation in conventional or laminar air flow rooms. Acyclovir was routinely administered to all patients. Systemic antifungal prophylaxis was fluconazole, itraconazole or liposomal amphotericin B, depending on the year of transplant. Prophylaxis against pneumocystis jiroveci (PCP) consisted of cotrimoxazole or pentamidine inhalation. All blood products were irradiated with 25 Gy. Cytomegalovirus (CMV)-negative patients received only CMV-negative blood products. CMVpositive patients were monitored at least weekly for CMV infection by PCR and/or antigenaemia assay. Preemptive therapy was started with 10 mg/kg gancyclovir per day after two consecutive positive PCR results or one positive antigenaemia assay. Neutropenic fever was treated with broadspectrum antibiotics.
Statistical considerations
All data were evaluated and updated as of August 2011. The primary endpoint of the analysis was OS.
Patient characteristics were expressed as median and range for continuous variables and frequencies for categorical variables. Categorical data were compared by w 2 test or Fisher's exact test. The curves for OS were estimated using the method of Kaplan-Meier. Comparison of curves was calculated using the log-rank test. The following factors were included in the analysis (only pre-transplant parameters): patients' age, donors' age, patients' sex, donors' sex, patient-donor sex constellation, standard-risk vs bad-risk cytogenetics, patients' CMV-serological status, donors' CMVserological status, stem cell source (BM vs PBSCs), HLA-match vs HLAmismatch, number of transplanted CD34 þ cells/kg BW, SIC vs RIC, ATG and time from diagnosis to allo-HSCT. 
RESULTS
Overall survival
Analysis of all 168 patients in CR at transplant revealed a Kaplan-Meier-estimated 5-yr OS of 66% (95% confidence intervals (CI): 54-78%) for patients transplanted from UD p39 years, 41% (95% CI: 25-57%) for UD 439 years, 65% (95% CI: 45-85%) for MRD p39 years and 34% (95% CI: 20-48%) for MRD 439 years (P ¼ 0.001, comparing all the four groups), Figure 1 . Five-year OS of patients with UD p39 years was significantly better than for those with MRD 439 years (66% vs 34%, P ¼ 0.001). Results of the univariate analysis for all 168 patients are summarized in Table 2 Further subgroup analyses including only patients X50 years (n ¼ 76), revealed similar findings with estimated 5-yr OS of 62% for UD p39 years and 26% for MRD 439 years (P ¼ 0.022) ( Figure 2 ) and Supplementary Figure S1 of Supplementary data.
Treatment-related mortality
For the entire group of 168 patients, estimated 5-year treatmentrelated mortality was 12% (95% CI: 4-20%) for patients transplanted from UD p39 years, 26% (95% CI: 12-40%) for UD 439 years, 13% (0-27%) for MRD p39 years and 35% (21-49%) for MRD 439 years, with a significant difference between UD p39 years and MRD 439 years, P ¼ 0.002.
Relapse
For the entire group of 168 patients, estimated 5-year relapse risk was 23% (95% CI: 11-35%) for patients transplanted from UD p39 years, 37% (95% CI: 23-51%) for UD 439 years, 35% (15-55%) for MRD p39 years and 33% (19-47%) for MRD 439 years, with a trend, but NS difference between UD p39 years and MRD 439 years, P ¼ 0.09.
GVHD and causes of death
The incidence of acute GVHD II-IV was 33.3%, 37.5%, 32.5% and 30.0% for UD p39 years, UD 439 years, MRD p39 years and MRD 439 years, respectively. The incidence of chronic GVHD was 33%, Table 4 ), show a trend to lower relapse-as well as GVHD-associated mortality in recipients of grafts from younger donors; however, the low number of events does not allow for valid statistical analysis.
DISCUSSION
In this retrospective long follow-up single center analysis of a uniform population of 168 AML patients in CR at the time of transplant, we find donor age and cytogenetic risk group to be the only factors significantly influencing 5-yr OS. Recipients of grafts from younger UD had significantly better outcomes compared with recipients of grafts from older sibling donors. The fact that more patients in the former group were transplanted in second CR or later may make these results even more significant. The lower 5-yr OS observed in patients who received grafts from MRD 439 years is partly a result of higher GVHD-associated mortality. The relatively low rate of GVHD-associated mortality in recipients of grafts from UD p39 years is probably due to inclusion of ATG in the conditioning regimens of 98% of UD p39 year transplants compared with 30% of MRD 439 years.
The incidence of relapse of underlying disease was higher in recipients of MRD 439 years. The reasons for this increase in relapse rate are unclear. None of the relevant patient characteristics known to increase relapse incidence (including cytogenetic risk, CR1 vs CR2 and beyond or conditioning intensity) disfavored recipients of MRD 439 years when compared with recipients of grafts from UD p39 years. Though 98% of recipients of UD p39 years received ATG, a recent randomized trial indicates that use of ATG can reduce the incidence and severity of GVHD without increasing relapse risk. 13 Donor gender and donor-recipient gender constellation had no significant impact on survival in our study. Female-to-male allo-HSCT has been reported to negatively impact OS; 14 however, this finding remains controversial. Two large National Marrow Donor Program (NMDP) retrospective studies, 4, 15 as well as a recent prospective randomized trial, examining the role of ATG in UD transplant, 16 found no significant effect of donor-recipient gender constellation on survival.
The negative impact of increasing donor age on outcome of allo-HSCT has been well studied in recipients of UD transplants. In the largest study so far, (n ¼ 6978 patients), 4 5-yr OS rates were 33%, 29% and 25% with MUD aged 18-30 years, 31-45 years and more than 45 years, respectively (P ¼ 0002). A similar effect was seen in HLA-mismatched cases (28%, 22% and 19%, respectively). Though the results of this retrospective NMDP study could not be confirmed by a later NMDP analysis with a smaller patient number (n ¼ 3857 patients), 15 findings from two prospective studies confirm the negative impact of increasing donor age on allo-HSCT outcome. 6, 16 In our study HLA-mismatch did not negatively influence survival. Though retrospective analysis from our group and others indicate that use of ATG may help overcome the negative impact of some degree of HLA-mismatch, [17] [18] [19] larger and probably prospective studies are necessary to determine whether HLAmismatched UD are preferable to other alternative donors and, if so, what kind and degree of HLA-mismatch can be tolerated.
Our study is surely limited by its retrospective character and moderate patient number; however, it highlights a possible advantage of young UD over elderly sibling donors. Our choice of median donor and patient ages as cutoff avoids arbitrary selection and generates results that are applicable in day-to-day donor selection. Our findings are in line with a recent study, reporting improved survival of older MDS patients (X50 years) with grafts from younger UD (o30 years) compared with older related donors (430 years). 20 Although standards for donor selection are generally supposed to be the same for related and UD, the significantly higher age of related donors may be associated with an increased rate of comorbidities and probably also increased risk of adverse effects during stem cell or BM collection procedures. UD are examined by 'neutral' physicians for their appropriateness to donate, whereas related donors are often evaluated by the centers treating the patients. This may increase the tendency to clear related donors who may otherwise be considered at risk. The decision to choose a younger UD instead of an elderly sibling with comorbidities would be easier and on a more solid basis, should our findings be confirmed in larger analyses. 
